Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Revenues	$ 20,920	$ 1,920
Operating expenses:
Cost of products sold	$ 2,434	$ 138
Cost, product and service, extensible enumeration	FOTIVDA U.S. product revenue, net	FOTIVDA U.S. product revenue, net
Research and development	$ 10,160	$ 5,797
Selling, general and administrative	17,337	15,100
Operating expenses	29,931	21,035
Loss from operations	(9,011)	(19,115)
Other income (expense), net:
Interest expense, net	(1,188)	(611)
Change in fair value of PIPE Warrant liability	0	(2,396)
Other income (expense), net	(1,188)	(3,007)
Net loss	$ (10,199)	$ (22,122)
Basic and diluted net loss per share
Net loss per share - basic (in dollars per share)	$ (0.30)	$ (0.81)
Net loss per share - diluted (in dollars per share)	$ (0.30)	$ (0.81)
Weighted average number of common shares outstanding - basic (in shares)	34,475	27,429
Weighted average number of common shares outstanding - diluted (in shares)	34,475	27,429
FOTIVDA U.S. product revenue, net
Revenues:
Revenues	$ 20,086	$ 1,066
Partnership licensing and royalty revenue
Revenues:
Revenues	$ 834	$ 854